ML 348 is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor with an IC50 of approximately 210nM, exhibiting 14-fold selectivity for LYPLA1 over LYPLA2[1-2]. ML 348 can be used to study protein palmitoylation and the biological functions of LYPLA1, and it significantly inhibits enzymatic activity in heart, lung, and kidney tissues[3-4].
In vitro, pretreatment of porcine alveolar macrophages (PAMs) with ML 348 (1μM) for 24–36 hours, followed by infection with porcine reproductive and respiratory syndrome virus (PRRSV-2; MOI=0.1), significantly suppressed viral ORF7 mRNA transcription and nucleocapsid protein (N protein) expression, while reducing viral titers[5]. Pretreatment of NRAS-mutant melanoma cells with ML 348 (≤12.5μM) for 6 hours did not significantly affect cell viability and did not markedly inhibit phosphorylation of the NRAS downstream signaling pathways ERK and AKT[6].
In vivo, chronic subcutaneous infusion of ML 348 (0.3mg/kg) for 28 days in 7-month-old symptomatic CAG140 Huntington's disease knock-in mice effectively crossed the blood-brain barrier, significantly improved motor coordination and alleviated anxiety-depressive-like behaviors, and reversed neuropathological changes[7]. Oral administration of ML 348 (70mg/kg) for 90 days in 12-month-old symptomatic 3KL α-synucleinopathy model mice significantly enhanced motor coordination, spatial memory, and long-term memory, and restored hippocampal synaptic plasticity[8].
References:
[1] Adibekian A, Martin BR, Chang JW, et al. Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 1 (LYPLA1). National Center for Biotechnology Information (US); 2010- 2013 Apr 08.
[2] Hulce JJ, Joslyn C, Speers AE, et al. An in Vivo Active Carbamate-based Dual Inhibitor of Lysophospholipase 1 (LYPLA1) and Lysophospholipase 2 (LYPLA2). National Center for Biotechnology Information (US); 2013 Dec 9.
[3] Won SJ, Davda D, Labby KJ, et al. Molecular Mechanism for Isoform-Selective Inhibition of Acyl Protein Thioesterases 1 and 2 (APT1 and APT2). ACS Chem Biol. 2016 Dec 16;11(12):3374-3382.
[4] Gu M, Jiang H, Tan M, et al. Palmitoyltransferase DHHC9 and acyl protein thioesterase APT1 modulate renal fibrosis through regulating β-catenin palmitoylation. Nat Commun. 2023 Oct 21;14(1):6682.
[5] Jing H, Liu Y, Song Y, et al. ZDHHC3-LYPLA1 regulates PRRSV-2 replication through reversible palmitoylation. Vet Microbiol. 2025 Feb;301:110368.
[6] Vujic I, Sanlorenzo M, Esteve-Puig R, et al. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget. 2016 Feb 9;7(6):7297-306.
[7] Virlogeux A, Scaramuzzino C, Lenoir S, et al. Increasing brain palmitoylation rescues behavior and neuropathology in Huntington disease mice. Sci Adv. 2021 Mar 31;7(14):eabb0799.
[8] Moors TE, Li S, McCaffery TD, et al. Increased palmitoylation improves estrogen receptor alpha-dependent hippocampal synaptic deficits in a mouse model of synucleinopathy. Sci Adv. 2023 Nov 15;9(46):eadj1454.
ML 348是一种选择性的、可逆的溶血磷脂酶1（LYPLA1）抑制剂，IC50约为210nM，对LYPLA1的选择性是对LYPLA2的14倍[1-2]。ML 348可用于研究蛋白质棕榈酰化修饰、LYPLA1的生物学功能，ML 348能显著抑制心、肺、肾组织的酶活性[3-4]。
在体外，ML 348（1μM）预处理猪肺泡巨噬细胞（PAMs）24–36小时，随后以猪生殖与呼吸综合征病毒（PRRSV-2；MOI为0.1）感染，显著抑制病毒ORF7 mRNA的转录和核衣壳蛋白（N蛋白）的表达，同时降低病毒滴度[5]。ML 348（≤12.5μM）预处理NRAS突变黑色素瘤细胞6小时，对细胞存活率无显著影响，且未明显抑制NRAS下游信号通路ERK和AKT的磷酸化[6]。
在体内，ML 348（0.3mg/kg）通过慢性皮下灌注给药28天，用于处理7月龄早期症状的CAG140亨廷顿病敲入小鼠。ML 348有效穿过血脑屏障，显著改善了小鼠的运动协调能力和焦虑抑郁样行为，并逆转了神经病理学变化[7]。ML 348（70mg/kg）通过口服给药90天，用于处理12月龄出现症状的3KL α-突触核蛋白病模型小鼠。ML 348显著改善了小鼠的运动协调能力、空间记忆和长期记忆，并恢复了海马突触可塑性[8]。